Literature DB >> 18925454

Do amyloid oligomers act as traps for misfolded proteins? A hypothesis.

James M Gruschus1.   

Abstract

Mounting evidence points to soluble peptide oligomers as the primary agents in various amyloid and prion diseases. Multiple mechanisms appear to contribute to the cytotoxic effects of these oligomers. Here, an additional, general mechanism is proposed - that soluble amyloid peptide oligomers serve as "all-purpose"beta strands that can interact with transiently unfolded or nascent proteins where interior beta-sheet edges are exposed. The proteins, trapped in misfolded states through this interaction, become substrates for ubiquitination, targeting them for proteasomal degradation. The increased load of ubiquitinated proteins could contribute to the impairment of the ubiquitin/proteasome system (UPS) seen in many amyloid-related diseases. This "misfolding trap" mechanism could be especially stressful in the endoplasmic reticulum, where the amyloid oligomers would compete with chaperones for nascent beta-sheet proteins. If the bound amyloid oligomer dissociates at some point after the misfolded protein is committed to the UPS pathway, the oligomer could then repeat the process, adding a catalytic aspect to the misfolding mechanism. Direct proof of this proposed mechanism requires detection of amyloid oligomer-beta-sheet protein complexes, and a co-immunoprecipitation experiment is proposed. This hypothesis supports therapies that increase amyloid oligomer degradation or sequestration, as well as therapies that upregulate chaperone activity, for combating amyloid-related diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925454      PMCID: PMC2575656          DOI: 10.1080/13506120802193746

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  55 in total

1.  Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide.

Authors:  T H Huang; D S Yang; N P Plaskos; S Go; C M Yip; P E Fraser; A Chakrabartty
Journal:  J Mol Biol       Date:  2000-03-17       Impact factor: 5.469

2.  Specificity in intracellular protein aggregation and inclusion body formation.

Authors:  R S Rajan; M E Illing; N F Bence; R R Kopito
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

3.  Natural beta-sheet proteins use negative design to avoid edge-to-edge aggregation.

Authors:  Jane S Richardson; David C Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

4.  Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.

Authors:  Martin J Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Pankaj D Mehta; Frances Prelli; David Quartermain; Thomas Wisniewski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

5.  'Rejuvenation' protects neurons in mouse models of Parkinson's disease.

Authors:  C Savio Chan; Jaime N Guzman; Ema Ilijic; Jeff N Mercer; Caroline Rick; Tatiana Tkatch; Gloria E Meredith; D James Surmeier
Journal:  Nature       Date:  2007-06-10       Impact factor: 49.962

6.  Atomic structures of amyloid cross-beta spines reveal varied steric zippers.

Authors:  Michael R Sawaya; Shilpa Sambashivan; Rebecca Nelson; Magdalena I Ivanova; Stuart A Sievers; Marcin I Apostol; Michael J Thompson; Melinda Balbirnie; Jed J W Wiltzius; Heather T McFarlane; Anders Ø Madsen; Christian Riekel; David Eisenberg
Journal:  Nature       Date:  2007-04-29       Impact factor: 49.962

7.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

Review 8.  Calcium and neurodegeneration.

Authors:  Mark P Mattson
Journal:  Aging Cell       Date:  2007-02-28       Impact factor: 9.304

Review 9.  Folding versus aggregation: polypeptide conformations on competing pathways.

Authors:  Thomas R Jahn; Sheena E Radford
Journal:  Arch Biochem Biophys       Date:  2007-06-08       Impact factor: 4.013

10.  Interaction of intracellular beta amyloid peptide with chaperone proteins.

Authors:  Virginia Fonte; Wadim Jan Kapulkin; Vadim Kapulkin; Andrew Taft; Amy Fluet; David Friedman; Christopher D Link
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

View more
  4 in total

1.  Amyloid β-induced FOXRED2 mediates neuronal cell death via inhibition of proteasome activity.

Authors:  SangMi Shim; WonJae Lee; HaeWon Chung; Yong-Keun Jung
Journal:  Cell Mol Life Sci       Date:  2010-10-23       Impact factor: 9.261

2.  Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains.

Authors:  Sharad P Adekar; Igor Klyubin; Sally Macy; Michael J Rowan; Alan Solomon; Scott K Dessain; Brian O'Nuallain
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

Review 3.  Exploring the link between glucocerebrosidase mutations and parkinsonism.

Authors:  Wendy Westbroek; Ann Marie Gustafson; Ellen Sidransky
Journal:  Trends Mol Med       Date:  2011-07-01       Impact factor: 11.951

4.  Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.

Authors:  Thai Leong Yap; James M Gruschus; Arash Velayati; Wendy Westbroek; Ehud Goldin; Nima Moaven; Ellen Sidransky; Jennifer C Lee
Journal:  J Biol Chem       Date:  2011-06-08       Impact factor: 5.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.